S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
NASDAQ:CLNN

Clene Stock Forecast, Price & News

$6.17
-0.19 (-2.99 %)
(As of 10/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.13
$6.49
50-Day Range
$6.17
$9.73
52-Week Range
$6.13
$17.82
Volume166,982 shs
Average Volume280,909 shs
Market Capitalization$379.41 million
P/E RatioN/A
Dividend YieldN/A
Beta0.11
30 days | 90 days | 365 days | Advanced Chart
Receive CLNN News and Ratings via Email

Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter.


Clene logo

About Clene

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLNN
Employees
63
Year Founded
N/A

Sales & Book Value

Annual Sales
$210,000.00
Book Value
$0.01 per share

Profitability

Net Income
$-19.28 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$379.41 million
Next Earnings Date
11/2/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

545th out of 1,361 stocks

Pharmaceutical Preparations Industry

256th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Clene (NASDAQ:CLNN) Frequently Asked Questions

Is Clene a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clene in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Clene stock.
View analyst ratings for Clene
or view top-rated stocks.

What stocks does MarketBeat like better than Clene?

Wall Street analysts have given Clene a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clene wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Clene's next earnings date?

Clene is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Clene
.

How were Clene's earnings last quarter?

Clene Inc. (NASDAQ:CLNN) posted its quarterly earnings data on Monday, August, 9th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.05. The business had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.07 million.
View Clene's earnings history
.

What price target have analysts set for CLNN?

5 equities research analysts have issued twelve-month price objectives for Clene's shares. Their forecasts range from $18.00 to $25.00. On average, they expect Clene's stock price to reach $21.80 in the next twelve months. This suggests a possible upside of 253.3% from the stock's current price.
View analysts' price targets for Clene
or view top-rated stocks among Wall Street analysts.

Who are Clene's key executives?

Clene's management team includes the following people:
  • Mr. Robert Etherington, CEO, Pres & Director (Age 54, Pay $504.83k)
  • Mr. Mark G. Mortenson, Co-Founder & Chief Science Officer (Age 63, Pay $473.33k)
  • Dr. Robert Glanzman M.D., Chief Medical Officer (Age 64, Pay $447.2k)
  • Dr. Jeong Ted, Chief Financial Officer (Age 50)
  • Mr. Jerry Miraglia J.D., Gen. Counsel & Corp. Sec.
  • Mr. Michael T. Hotchkin, Chief Devel. Officer
  • Ms. Mary Anne Mcneil, Head of HR

What is Clene's stock symbol?

Clene trades on the NASDAQ under the ticker symbol "CLNN."

How do I buy shares of Clene?

Shares of CLNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clene's stock price today?

One share of CLNN stock can currently be purchased for approximately $6.17.

How much money does Clene make?

Clene has a market capitalization of $379.41 million and generates $210,000.00 in revenue each year. The company earns $-19.28 million in net income (profit) each year or ($1.23) on an earnings per share basis.

How many employees does Clene have?

Clene employs 63 workers across the globe.

What is Clene's official website?

The official website for Clene is clene.com.

Where are Clene's headquarters?

How can I contact Clene?

Clene's mailing address is UNIT 902 9/F LUCKY BUILDING 39 WELLINGTON STREET, HONG KONG K3, . The company can be reached via phone at 801-676-9695 or via email at [email protected].


This page was last updated on 10/16/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.